Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORINYL 1+35 28-DAY vs ESTARYLLA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Norethindrone is a progestogen that suppresses gonadotropin release, inhibiting ovulation; ethinyl estradiol is an estrogen that provides negative feedback on the hypothalamic-pituitary-ovarian axis, further suppressing ovulation and altering cervical mucus and endometrial thickness.
Estarylla is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It suppresses gonadotropin release (FSH and LH) via estrogen and progestin, inhibiting ovulation. Additionally, it increases cervical mucus viscosity and alters endometrial receptivity, impeding sperm penetration and implantation.
Prevention of pregnancy,Treatment of moderate acne vulgaris in women who desire an oral contraceptive
FDA-approved: Prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.,Off-label: Acne vulgaris (for norgestimate-containing pills), management of menstrual disorders (e.g., dysmenorrhea, abnormal uterine bleeding), hormone therapy for transgender women (non-standardized).,Note: Off-label uses are not FDA-approved for this specific formulation.
One tablet orally once daily for 28 consecutive days (21 active tablets followed by 7 inert tablets).
One tablet (0.02 mg ethinyl estradiol and 0.15 mg desogestrel) orally once daily for 21 days, followed by 7 days of placebo. Hormone-free interval of 7 days.
Norethindrone: 7-8 hours (terminal half-life); steady state achieved after 5 days. Ethinyl estradiol: biphasic with terminal half-life of 13-27 hours (mean ~17 hours). Clinical context: dosing interval of 24 hours allows stable hormone levels after first cycle.
Terminal elimination half-life of ethinyl estradiol is approximately 13-16 hours; clinical context: steady-state achieved within 5-7 days
Norethindrone is primarily metabolized via reduction and conjugation; ethinyl estradiol is metabolized by CYP3A4 and undergoes conjugation. Both are hepatically eliminated.
Ethinyl estradiol is primarily metabolized by CYP3A4, with conjugation to glucuronides and sulfates. Norgestimate is rapidly metabolized to its active metabolite, norelgestromin, and further to levonorgestrel; involvement of CYP2C19 and CYP3A4 in norgestimate metabolism is noted.
Renal: 50-60% (conjugates and metabolites), Fecal: 30-40% (biliary elimination of norethindrone and ethinyl estradiol conjugates); total clearance ~4-6 m L/min/kg.
Renal: ~55% as metabolites, ~27% unchanged; Fecal: ~45% as metabolites
Norethindrone: 80-85% bound to albumin and SHBG; Ethinyl estradiol: 95-98% bound to albumin (not strongly to SHBG).
Ethinyl estradiol: 97-98% bound to albumin, with minor binding to sex hormone-binding globulin
Norethindrone: 2-4 L/kg; Ethinyl estradiol: 2.5-5 L/kg; both indicate extensive tissue distribution.
Ethinyl estradiol: approximately 2.8 L/kg; indicates extensive tissue distribution
Norethindrone: 64-67% (oral, first-pass metabolism); Ethinyl estradiol: 38-48% (oral, extensive first-pass conjugation); food does not significantly alter bioavailability.
Oral: approximately 55% due to first-pass metabolism; consistent in healthy females
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); contraindicated in acute renal failure or significant renal disease due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in severe renal impairment or end-stage renal disease due to lack of data.
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). Use with caution in Child-Pugh class A (mild hepatic impairment) as metabolism may be reduced; monitor for adverse effects.
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). Use with caution in Child-Pugh class A; dose adjustment not specifically defined, but alternative contraception recommended.
Not indicated for use before menarche. For postmenarchal adolescents, dose is same as adults: one tablet orally once daily for 28 days.
Approved for use in postmenarchal adolescents: same dosing as adults (one tablet daily for 21 days, then 7 days placebo). No weight-based dosing required.
Not indicated for use after menopause. In perimenopausal women, same adult dosing applies; monitor for increased risk of thromboembolism, hypertension, and carbohydrate intolerance.
Not indicated in postmenopausal women. No specific geriatric dosing; contraindicated in women over 60 years due to increased thromboembolic risk.
Cigarette smoking increases the risk of serious cardiovascular adverse events from combined hormonal contraceptive use. This risk increases with age, especially in women over 35, and with the number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Cigarette smoking increases the risk of serious cardiovascular side effects from combination oral contraceptives. This risk increases with age (especially in women over 35 years of age) and with the number of cigarettes smoked. Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic disorders; liver disease; hypertension; gallbladder disease; carbohydrate and lipid effects; headache; irregular bleeding; ectopic pregnancy; depression; cervical cancer; hereditary angioedema; chloasma; retinal thrombosis; monitoring of blood pressure, glucose, lipids, liver function.
Thrombotic disorders: Increased risk of venous thromboembolism (VTE) and arterial thromboembolism (e.g., MI, stroke). Discontinue if thrombotic event occurs.,Cardiovascular disease: Avoid in women with uncontrolled hypertension, diabetes with vascular involvement, or history of thromboembolic disease.,Cigarette smoking: Strongly advise cessation, especially in women over 35.,Liver disease: Discontinue if jaundice or cholestasis develops; contraindicated in acute viral hepatitis or severe cirrhosis.,Hormone-dependent malignancies: Increased risk of breast cancer (current use) and cervical cancer; avoid if known or suspected breast cancer.,Gallbladder disease: Increased risk of gallstones.,Carbohydrate and lipid metabolism: Monitor glucose and lipids in predisposed patients; may impair glucose tolerance and increase triglycerides.,Headache: Evaluate if new-onset or worsening migraine, especially with focal neurological symptoms.,Uterine bleeding: Rule out pregnancy if amenorrhea occurs; irregular bleeding may require evaluation.,Depression: Monitor for mood changes; discontinue if severe depression recurs.,Angioedema: Risk in women with hereditary angioedema.
Thrombophlebitis or thromboembolic disorders; cerebrovascular or coronary artery disease; known or suspected breast carcinoma; undiagnosed abnormal genital bleeding; pregnancy; liver tumors or active liver disease; known hypersensitivity; concomitant use with hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir with or without dasabuvir.
Known or suspected pregnancy,Current or past venous thrombosis (e.g., deep vein thrombosis, pulmonary embolism),Current or past arterial thrombosis (e.g., myocardial infarction, stroke) or prodromal conditions (e.g., angina, transient ischemic attack),Known thrombophilic disorders (e.g., Factor V Leiden, prothrombin mutation, antithrombin deficiency),History of cerebrovascular or coronary artery disease,Uncontrolled hypertension (sustained >160/100 mm Hg),Diabetes mellitus with nephropathy, retinopathy, neuropathy, or other vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura) in women over 35,Current or past breast cancer, or other estrogen- or progestin-sensitive cancer,Active liver disease (e.g., acute viral hepatitis, severe cirrhosis) or benign/malignant liver tumors,Undiagnosed abnormal uterine bleeding,Hypersensitivity to any component of Estarylla,Use of highly active antiretroviral therapy (HAART) containing ritonavir or direct-acting antivirals for hepatitis C (e.g., ombitasvir/paritaprevir/ritonavir) due to potential for hepatotoxicity
No significant food interactions. Grapefruit juice may increase estrogen levels; advise limited consumption. Take with food to reduce gastrointestinal upset. Avoid St. John's Wort as it may reduce contraceptive efficacy.
There are no known significant food interactions. Grapefruit juice may increase estrogen levels but clinical significance is unclear; consider moderate intake.
First trimester: No increased risk of major birth defects from inadvertent exposure. Second and third trimesters: Avoid use due to risk of fetal harm from estrogen/progestin exposure; association with placental abruption, fetal growth restriction, and preterm delivery.
Estarylla (ethinyl estradiol/levonorgestrel) is a combined oral contraceptive. Use during pregnancy is contraindicated. First trimester: No strong evidence of major malformations from inadvertent exposure, but increased risk of cardiovascular and limb defects in some studies. Second and third trimesters: Associated with fetal harm, including cardiovascular effects (e.g., congenital heart defects) and possible estrogenic effects, though data are limited. Postnatal effects: Potential long-term developmental effects unknown. Overall risk is low but not zero; avoid use in pregnancy.
Excreted in breast milk in small amounts; M/P ratio not established for norethindrone/ethinyl estradiol combination. Use with caution; may reduce milk production. Consider alternative contraception during breastfeeding.
Estarylla is excreted in breast milk in small amounts (ethinyl estradiol: M/P ratio ~0.2; levonorgestrel: M/P ratio ~0.3-0.4). Combined hormonal contraceptives may reduce milk production and affect milk composition, especially in early postpartum. Use is generally not recommended until breastfeeding is well-established (at least 6 weeks postpartum). For later use, progestin-only methods are preferred. Monitor infant for jaundice and growth.
Contraindicated in pregnancy; no dose adjustments recommended as use is not advised. Pharmacokinetic changes (increased clearance, volume of distribution) are relevant only if inadvertent exposure occurs, but no dose adjustment is standard.
Estarylla is contraindicated in pregnancy. No dosing adjustments are recommended because it should not be used. Pregnancy alters pharmacokinetics of oral contraceptives (e.g., increased volume of distribution, altered hepatic metabolism), but no dose changes are indicated due to contraindication. If inadvertently taken, discontinue immediately.
Norinyl 1+35 (norethindrone 1 mg/ethinyl estradiol 35 mcg) is a monophasic combined oral contraceptive. Missed pill management: if one active pill missed, take as soon as remembered; if two missed in week 1 or 2, take two pills on day remembered and two on next day; if two missed in week 3 or three missed at any time, discard remainder of pack and start new pack next day. Use backup contraception for 7 days after any miss. Advise to take at same time daily to maintain consistent hormone levels. Monitor for thromboembolic events; absolute contraindication if history of DVT/PE or migraine with aura. Prescribe with caution in smokers over 35 years old.
Estarylla is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It is indicated for prevention of pregnancy. Monitor for thromboembolic events, especially in smokers over 35. Counsel on missed dose management: take as soon as remembered, use backup contraception if more than 24 hours late. May reduce menstrual cramps and acne. Not recommended in patients with history of estrogen-dependent neoplasia, liver disease, or uncontrolled hypertension.
Take one tablet daily at the same time, preferably after the evening meal to reduce nausea.,Start the first pill on the first day of menstrual period for immediate contraceptive protection.,If you miss a pill, refer to the package insert or call your healthcare provider.,Use a back-up contraceptive method (e.g., condoms) for the first 7 days if starting after day 5 of your cycle.,Common side effects include nausea, breast tenderness, and breakthrough bleeding, which often improve after 3 months.,Seek medical attention for severe abdominal pain, chest pain, leg swelling, or severe headache.,Do not smoke while taking this medication, especially if over 35 years old, due to increased risk of blood clots.,This medication does not protect against HIV or other sexually transmitted infections.
Take one pill daily at the same time each day.,If you miss a pill, take it as soon as remembered; use backup contraception if more than 24 hours late.,Do not smoke while taking this medication, especially if over 35.,Report any signs of blood clots: leg pain, chest pain, shortness of breath, or sudden vision changes.,This medication does not protect against HIV or other STDs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORINYL 1+35 28-DAY vs ESTARYLLA, answered by our medical review team.
NORINYL 1+35 28-DAY is a Combined Oral Contraceptive that works by Norethindrone is a progestogen that suppresses gonadotropin release, inhibiting ovulation; ethinyl estradiol is an estrogen that provides negative feedback on the hypothalamic-pituitary-ovarian axis, further suppressing ovulation and altering cervical mucus and endometrial thickness.. ESTARYLLA is a Combined Oral Contraceptive that works by Estarylla is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It suppresses gonadotropin release (FSH and LH) via estrogen and progestin, inhibiting ovulation. Additionally, it increases cervical mucus viscosity and alters endometrial receptivity, impeding sperm penetration and implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORINYL 1+35 28-DAY and ESTARYLLA depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORINYL 1+35 28-DAY is: One tablet orally once daily for 28 consecutive days (21 active tablets followed by 7 inert tablets).. The standard adult dose of ESTARYLLA is: One tablet (0.02 mg ethinyl estradiol and 0.15 mg desogestrel) orally once daily for 21 days, followed by 7 days of placebo. Hormone-free interval of 7 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORINYL 1+35 28-DAY and ESTARYLLA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORINYL 1+35 28-DAY is classified as Category C. First trimester: No increased risk of major birth defects from inadvertent exposure. Second and third trimesters: Avoid use due to risk of fetal harm from estrogen/progestin exposu. ESTARYLLA is classified as Category C. Estarylla (ethinyl estradiol/levonorgestrel) is a combined oral contraceptive. Use during pregnancy is contraindicated. First trimester: No strong evidence of major malformations f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.